Lina Zhang,1– 3,* Ruibin Wu,2,3,* Tenghui Ma,2,3 Wenwen Fu,2,3 Jiamin Chen,2,3 Lingling Li,2,3 Qing He2,3 

1The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, 510080, People’s Republic of China; 2Department of Clinical Nutrition and Microbiome; Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, People’s Republic of China; 3Key Laboratory of Human Microbiome and Chronic Diseases (Sun Yat-sen University), Ministry of Education, Guangzhou, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Qing He, Email heqing5@mail.sysu.edu.cn

Objective: To explore the active substances and targets of Danbie Capsules in Endometriosis therapy.
Methods: This study was conducted through TCMSP and published literature screened and obtained 183 active substances of Danbie Capsules, combined and intersected with Endometriosis target genes collected and screened in the GEO database, obtained 24 target genes for Endometriosis treatment, and mapped the target network map of Danbie Capsules active substances against Endometriosis. The network was analyzed with the aid of Cytoscape version 3.9.1. With the aid of the platform of the STRING data analysis, PPI network analysis was conducted on 24 anti-Endometriosis targets of the Danbie Capsules.
Results: The research results obtained three critical active substances, namely, Quercetin, β-sitosterol, and Luteolin. Seven critical targets were identified, and two representative genes (TP53 and AKT1) have been verified in Macromolecular docking and immunohistochemical verification.
Conclusion: The active substances of Danbie Capsules in the treatment of Endometriosis are Quercetin, β-sitosterol and Luteolin, and the main targets are TP53 and AKT1.

Keywords: danbie capsules, endometriosis, network pharmacology